NEW ORLEANS -- Dogs may be good at sniffing out some types of cancer, but that skill doesn't appear to transfer to detecting hypoglycemic events, according to research presented here.

From www.medpage.com

Nyhetsinfo

www red DiabetologNytt

Diabetic dog alerts had a low sensitivity and positive

...

NEW ORLEANS — Pioglitazone halved the progression to diabetes in people with insulin resistance and cerebrovascular disease, new data from the Insulin Resistance Intervention after Stroke (IRIS) trial show.

From www.medscape.com

Nyhetsinfo

www red DiabetologNytt

 

The new findings from the 5-year

...

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Google N Engl J Med to read in full text free or just click on Hypertext in the text

Nyhetsinfo SA
www red DiabetologNytt

Christoph Wanner, M.D., Silvio E. Inzucchi, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Maximilian von

...

ADA: Liraglutide Reduces Risk of Heart Events

Widely-anticipated cardiovascular outcomes trial delivers positive result.

From www.medpage.com

Nyhetsinfo

www red DiabetologNyt

                        Action Points

Note that this large, randomized trial of liraglutide versus placebo as add-on therapy to standard-of-care

...
4.16 pm local time ADA 

Liraglutide, a glucose-lowering drug, has been shown to safely and effectively lower overall heart attack, stroke or cardiovascular death among oeople with T2DM at high risk for cardiovascular disease, according to results from Liraglutide Effect and Action in Diabetes -

...

Today's Top News from Fiercemedical.com

Nyhetsinfo www red DiabetologNytt

 

1. Medtronic presents pivotal artificial pancreas data at ADA, as Insulet details its own plans

Medtronic reported pivotal data for its hybrid closed-loop system at the American Diabetes Association conference in New

...

Critical Hypoglycemia in Hospitalized Patients with Diabetes: Early Outcomes of Standardized Reporting and Management.

Nyhetsinfo

www red DiabetologNytt

Author Block: KATHERINE A. ARAQUE, DEEPAK KADAYAKKARA, NINO GIGAURI, KASIA J. LIPSKA, GREGORY BULLER, CLARE A. FLANNERY, Bridgeport, CT, New

...

“Intra-day” and “Day-to-Day” Glucose Variability Both Increase Oxidative Stress Determined by d-ROMs in Type 2 Diabetes: A Cross-Sectional Study.

Nyhetsinfo
www red DiabetologNytt

Author Block: MAKOTO OHARA, TOMOYASU FUKUI, MOTOSHI OUCHI, KENTARO WATANABE, TATSUYA SUZUKI, TAKESHI YAMAMOTO,

...

Today ADA announced the 8 top abstracts. They are selected from 3100 abstracts submitted this year. They represent the best of the best cutting-edge research the ADA Meeting has to offer, covering a range of basic and clinical science related to important aspects of diabetes care.

Two abstracts about

...
...

The EMPA-REG Outcome trial empa, a SGLT2-inhibitor, showed in Sept 2015 great cardiovascular benefits. Changes in energy metabolism could explain how SGLT2 inhibition improves cardiovascular outcomes, according to prof Ferrannini, Pisa, Italy.

Nyhetsinfo

www red DiabetologNytt

 

"Empa improves the

...

Options for the sequence of medications that should following the ubiquitous first-line use of metformin in most patients with type 2 diabetes was the subject of a packed symposium this morning at the  American Diabetes Association (ADA) 2016 Scientific Sessions.

From www.medscape.com

Nyhetsinfo

...

Beyond A1CWhy Quality of Life Matters

 

Health-related quality of life (HRQOL) is an important area of investigation that has gained increasing recognition and is a critical element of diabetes research, treatment and care, according to experts at the Symposium, “Beyond A1CWhy Quality of Life

...

Innovative Approaches to Treating Type 1 Diabetes Addressed in 

Beta-Cell Replacement Presentations

 

Transplanting islet cells from pigs into humans and developing “universal donor” stem cell lines are two innovative approaches being explored for replacing deteriorating beta cells in people with

...

Using Novel Flash Glucose-Sensing Technology Reduces Hypoglycemia in Individuals with Type 1

Poster at the Meeting

Nyhetsinfo

www red DiabetologNytt 

 

JAN BOLINDER, RAMIRO ANTUNA, NEL GEELHOED-DUIJVESTIJN, STEPHAN MATTHAEI, RAIMUND WEITGASSER, Stockholm, Sweden, Madrid, Spain, The Hague,

...

Empagliflozin and Microvascular Outcomes in EMPA-REG OUTCOME

Author Block: CHRISTOPH WANNER, CHRISTOPHER LEE, HANS J. WOERLE, MICHAELA MATTHEUS, SILVIO E. INZUCCHI, BERNARD ZINMAN, Würzburg, Germany, Ingelheim, Germany, New Haven, CT, Toronto, ON, Canada

In EMPA-REG OUTCOME, empagliflozin, given

...

Press release

The first long-term implantable CGM (continuous glucose monitor) will be launched this month in Sweden, Norway and Denmark.

How does it compare to current CGMs?

Eversense will be the “world’s first long-term wear sensor.” Current CGMs in market include glucose sensors from Abbott

...

Press release 

Lanserar nu moln-till-moln integration med Abbotts Freestyle Libre

Idag tar Diasend ett nytt kliv i sin strävan att underlätta livet med diabetes, för både patienter och vårdgivare. Detta genom att introducera en moln-till-moln integration. I samarbete med Abbott Diabetes Care

...

Large observational study using real-world data finds no increased risk for hospitalized heart failure (hHF) among patients who initiated use of DPP-4 inhibitors, compared to other antihyperglycemics.

First study author Senwee Toh, ScD, of Harvard Medical School wrote, “In this large

...

Closed-loop systems for type 1 diabetes will be the new future in a couple of years, according todays session. T1DM is 24 h/7/365 day disease with demanding focuse on the blood glucose, it should not be too high and not to low. Always on a daily basis, minute-to-minute the patient should be aware how

...

 The session declared that high glucose is responsible for diabetic retinopathy - but how they exactly cause it is not known, according to Prof renu, Univ Kresge, and said that high glucose can cause epigenetic modifications that change the way genes act and the proteins they code for. If we can

...

At a session yesterady the experts said the risk factors should be better more intensively treated.

European guidelines yhis year recommends a routine HbA1c in alla patients with ST elevation myocardial infarction and non-ST elevation acute coronary syndrome.

Many guidelines recommend systolic blood

...

The most prescribed oral agent for T2DM metformin may also improve cardiovascular outcome, and reduce cancer risk. Metformin is underutilized according to a meeting yesterday when experts were discussing the growing use of metformin. New labelling in US indicates metformin use for patients with

...

KEY FACTS

29,1 millions have diabetes,

9,3% of the poipulation,

95% T2DM, and 1 of 4 do not know that they have T2DM.

1,4 million Americans are diagnosed with diabetes every year.  

Age 12 years of all people 12,3% in this age group have diabetes.

Age 65 years or older 25,9% of all people in this

...

Online Reporting

It  is a great pleasure to report from ADA, the worlds largest diabetes conference. Writing in English-American because tecknical problems with the computer, the a, a, o, the last letters in the alphabet are missing. Sorry for that. The Conference will start in a couple of hours.

The

...